# Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

> **NCT07215910** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 408 (estimated)

## Conditions studied

- Astrocytoma, IDH-Mutant, Grade 3

## Interventions

- **RADIATION:** Intensity-Modulated Radiation Therapy
- **RADIATION:** Volume Modulated Arc Therapy
- **RADIATION:** Pencil Beam Scanning
- **PROCEDURE:** Intensity-Modulated Proton Therapy
- **DRUG:** Temozolomide
- **DRUG:** Vorasidenib
- **DRUG:** Placebo Administration
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT07215910
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-20
- **Primary completion:** 2033-05-31
- **Final completion:** 2040-01
- **Target enrollment:** 408 (ESTIMATED)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07215910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07215910, "Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07215910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*